Lenvatinib (also known as E7080) is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors used for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well.
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.[1]
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.[2]
Multikinase inhibitors: a new option for the treatment of thyroid cancer.[3]
References:
[1] J.Matsui, et al, Int. J. Cancer, 2008, 122(3), pp 664-671.
[2] J.Matusui, et al, Clin. Cancer Res., 2008, 14(17), pp 5459-5465.
.png)
